

## Number of shares in BioGaia

In accordance with the warrant program approved by the AGM as of 8 May 2012 redemption of warrants during June 2015 has led to an increase of BioGaia's share capital by SEK 65,500 to a total of SEK 17,336,462.

The number of shares has increased with 65,500 class B-shares through which the number of class B-shares now amounts to 16,595,794 with no change in the number of class A-shares, i.e. 740,668.

The total number of shares is thereby today, the last trading date of the month, 17 336 462 shares which is equivalent to 24,002,474 votes.

### For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

### Latest press releases from BioGaia

2015-06-24	BioGaia subsidiary IBT takes rapid steps in development of a drug for premature infants
2015-06-12	BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics AB
2015-05-08	Annual General Meeting of BioGaia

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 30 June 2015 9:00 am CET.

**BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. [www.biogaia.com](http://www.biogaia.com)**